Business Standard

AstraZeneca still aiming for Oxford Covid-19 vaccine by year-end, says CEO

Soriot sought to reassure investors after the company and its partner confirmed earlier this week that they had temporarily stopped giving people the experimental shot

AstraZeneca Chief Executive Officer Pascal Soriot
Premium

The reality is we all have to be very patient and see how it unfolds, AstraZeneca CEO Pascal Soriot said

Suzi Ring and James Paton | Bloomberg
AstraZeneca Plc Chief Executive Officer Pascal Soriot said the coronavirus vaccine the company is developing with the University of Oxford could still be ready before the end of the year after pausing its trials due to a possible serious neurological problem in one participant.
 
Speaking at an online conference Thursday, Soriot sought to reassure investors after the company and its partner confirmed earlier this week that they had temporarily stopped giving people the experimental shot.
 
The trial was halted after a person in the UK who was participating in it got sick, triggering a review of safety data. Though such

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in